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Abstract
Sotos syndrome is an overgrowth condition characterized by cardinal features including excessive
growth during childhood, macrocephaly, distinctive facial gestalt and various degrees of learning
difficulty, and associated with variable minor features. The exact prevalence remains unknown but
hundreds of cases have been reported. The diagnosis is usually suspected after birth because of
excessive height and occipitofrontal circumference (OFC), advanced bone age, neonatal
complications including hypotonia and feeding difficulties, and facial gestalt. Other inconstant clinical
abnormalities include scoliosis, cardiac and genitourinary anomalies, seizures and brisk deep tendon
reflexes. Variable delays in cognitive and motor development are also observed. The syndrome may
also be associated with an increased risk of tumors. Mutations and deletions of the NSD1 gene
(located at chromosome 5q35 and coding for a histone methyltransferase implicated in
transcriptional regulation) are responsible for more than 75% of cases. FISH analysis, MLPA or
multiplex quantitative PCR allow the detection of total/partial NSD1 deletions, and direct
sequencing allows detection of NSD1 mutations. The large majority of NSD1 abnormalities occur
de novo and there are very few familial cases. Although most cases are sporadic, several reports of
autosomal dominant inheritance have been described. Germline mosaicism has never been
reported and the recurrence risk for normal parents is very low (<1%). The main differential
diagnoses are Weaver syndrome, Beckwith-Wiedeman syndrome, Fragile X syndrome, Simpson-
Golabi-Behmel syndrome and 22qter deletion syndrome. Management is multidisciplinary. During
the neonatal period, therapies are mostly symptomatic, including phototherapy in case of jaundice,
treatment of the feeding difficulties and gastroesophageal reflux, and detection and treatment of
hypoglycemia. General pediatric follow-up is important during the first years of life to allow
detection and management of clinical complications such as scoliosis and febrile seizures. An
adequate psychological and educational program with speech therapy and motor stimulation plays
an important role in the global development of the patients. Final body height is difficult to predict
but growth tends to normalize after puberty.
Disease name and synonyms
Sotos syndrome (OMIM 117550)
Cerebral Gigantism syndrome
Definition
Sotos syndrome is a childhood overgrowth condition,
first described in 1964 by Sotos et al [1], though the first
patient described may have been reported in 1931 [2].
The four major diagnostic criteria were established in
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assessment of 41 typical cases: overgrowth with advanced
bone age, macrocephaly, characteristic facial appearance,
and learning difficulties. These clinical criteria remained
the cornerstone for the diagnosis of Sotos until 2002. The
recent identification of NSD1 mutations and deletions [4]
has allowed re-evaluation of the features of this condition
[5-9]. In 2005, Tatton-Brown and the Childhood Over-
growth Collaboration Consortium reviewed the clinical
features of 239 Sotos cases with NSD1 abnormalities.
They confirmed that overgrowth (including height and
occipito-frontal circumference), dysmorphism and learn-
ing disability were present in 90% of these NSD1-positive
individuals, with a wide spectrum of associated features
including macrocephaly, advanced bone age, neonatal
jaundice and hypotonia, seizures, scoliosis, cardiac
defects and genitourinary anomalies [10].
Epidemiology
Sotos syndrome is probably one of the most common
overgrowth conditions, after the Beckwith-Wiedemann
syndrome. The exact birth prevalence remains unknown.
Hundreds of cases are reported. The literature on Sotos
syndrome, before the identification of the NSD1 gene
responsibility, has to be read carefully since it is mixed
with publications that evidently do not deal with the
Sotos syndrome.
Clinical description
For forty years, the diagnosis of Sotos syndrome has been
based on the subjective evaluation of clinical features.
However, although the combination of craniofacial fea-
tures may be distinctive, the other components are non-
specific. This lack of specific clinical features was often the
center of nosologic discussion [3,11]. Recently, Tatton-
Brown and Rahman analyzed helpfully the clinical fea-
tures of a large series of more that two hundred Sotos syn-
drome cases with proven abnormalities in NSD1 [10,12].
Generally, pregnancy is described as normal; however,
toxemia or pre-eclampsia is mentioned in several cases
[11]. Mean gestational age is normal (39 weeks) but the
infants are large for their gestational age. According to
Cole and Hughes [3], birth length, weight, and occipito-
frontal circumference (OFC) are respectively 3.2, 1.0, and
1.8 standard deviations above the mean. Length is likely
more increased than weight. Indeed, the birth weight of
76% of the 107 Sotos cases reported by Tatton-Brown was
less than the 98th centile and the mean birth weight centile
was 75th-91st [12]. In the neonatal period, many infants
experience early feeding difficulties (40% required tube
feeding [3]), variable degree of congenital hypotonia,
jaundice by hyperbilirubinemia or hypoglycemia.
Throughout childhood, the advance growth is particularly
pronounced in the first year of life, after which it stabilizes
with a height consistently above the 97th centile between
age 2 and 6 years. This childhood overgrowth may be
absent (90% of the affected individuals have height and/
or head circumference >2SD above the mean in Tatton-
Brown series [10]). Growth in height and weight tends to
normalize at puberty, probably because of the epiphysal
fusion. Final height is, in the majority of cases, within the
high normal range [13], particularly in females, in whom
the growth pattern correlates well with the presence of
advanced bone age and early puberty. Macrocephaly and
large hands and feet are also consistent features [1]. Crani-
ostenosis by premature fusion of lambdoid, sagittal and
coronal sutures has been reported [11]. The reported inci-
dence of advanced bone age in Sotos cases varies from
74% to 100% of cases, and this variability is probably
related to the frequency, timing and method of assess-
ment. This feature is present in 76% of the NSD1-positive
individuals [10]. Bone age is often described as dyshar-
monic with the phalangeal age being in advance in com-
parison with the carpal age. X-rays of the hand are also
useful for metacarpophalangeal profiles, which have been
reported to produce patterns that evokes Sotos syndrome
[14].
The overall craniofacial features are distinctive, especially
between one and six years of age. In infancy, the face is
round with disproportionate prominence of forehead and
become longer in adolescence, with prominence of the
pointed chin. Macrodolichocephaly, receding hairline,
apparent hypertelorism with down slanting palpebral fis-
sures, prominent jaw, malar flushing, anteverted nostrils,
mild micrognathia, high arched palate and large ears are
commonly identified. OFC is between the 98th and 99.6th
centile in infancy, childhood and adulthood, and is below
the 91st centile in only 7% of the series of Tatton-Brown
[10], 60% having an OFC greater than the 99.6th percen-
tile.
Most patients have a non progressive neurological dys-
function manifested by clumsiness and poor coordina-
tion. Cole and Hughes [3] reported a mean
developmental/intelligence quotient (DQ/IQ) of 78
Sotos cases with a range 40–129 (n = 23) and, recently, de
Boer et al [15] found that the mean IQ, in 21 individuals
with NSD1 gene alterations was 76 (range 47–105). Delay
in expressive language and motor development during the
infancy is particularly common. The degree of learning
disability appears extremely variable. Among the 239
NSD1-positive individuals in Tatton-Brown series [10],
97% presented learning difficulties. Delay in walking
until after 15 months of age and speech delay until after
2.5 years are usual. Recently was reported a family with
segregation of a NSD1 mutation with significant over-
growth but without mental deficiency [16]. Seizures are
found in about 50% of patients, but in half the cases, theyPage 2 of 6
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be a component [17,18]. Psychiatric manifestations
including social inhibition or psychosis have been also
noticed [19,20]. Dilatation of the cerebral ventricles is
common. Other non-specific neurological abnormalities
include absent corpus callosum, prominent cortical sulci,
cavum septum pellucidum and cavum velum interpositi
[17]. Minor neuroimaging anomalies are frequently
found in Sotos syndrome: prominence of the trigone in
90% of cases, prominence of the occipital horns in 75%
and ventriculomegaly in 63% of cases [21,22]. Brisk deep
tendon reflexes (sometimes even with a few beats of
clonus) are often observed.
Variable degrees of scoliosis are present in 30% of the
NSD1-positive cases [10]. Genu valga or vara, congenitally
dislocated hips, propensity to fracturing with minimal
trauma are often reported; one case of cervical instability
has been reported [11,23]. Finger nails are usually deep
and brittle. The incidence of congenital heart defects in
Sotos syndrome is approximately 8% in the series of Cole
and Hughes [3], but 21% in the series of Tatton-Brown
[10]. The most common defects are septal defects and pat-
ent arterial duct. One patient is reported with Wolff-Par-
kinson-White pattern [24]. Recurrent upper respiratory
infections and otitis media are frequent, leading to some
degree of conductive hearing loss. Constipation is com-
mon and may request investigation. Genitourinary anom-
alies including renal anatomical anomalies (bifid, duplex
or absent kidneys, vesico-ureteric reflux, pelvo-ureteric
junction obstruction), cystic kidneys and genital anoma-
lies such as hypospadius and cryptorchidism [25], are
present in 15% of children with NSD1 abnormalities [10].
Overgrowth syndromes are often associated with neo-
plasms (Beckwith-Wiedemann syndrome with over-
expression of IGF-2 and Simpson-Golabi-Behmel with
GPC3 mutations [26]). Initial reports suggested a neo-
plasm frequency of 7% in Sotos patients [27]. In a survey
of 224 patients with Sotos syndrome, however, the malig-
nancy risk was found lower than 2.2% [28]. Cohen
reviewed the reported neoplasias critically and suggested
a tumor frequency in patients with Sotos syndrome of
about 3.9% (more than in the general population) [29].
Sotos cases with NSD1 anomalies have been reported
with small cell lung cancer [12], ganglioglioma, neurob-
lastoma in two cases [7,30], and acute myelocytic leuke-
mia [31]. In the large series of Tatton-Brown, three
saccrococcygeal teratomas, one presacral ganglioneuroma
one neuroblastoma and one acute lymphocytic leukemia
occurred in children with confirmed NSD1 mutation [12].
Thus, the risk of tumors in childhood appears low but the
relative risk of sacrocoggygeal teratomas and neuroblast-
oma may be increased [10,32].
Laboratory findings
No biochemical or endocrinological markers have been
documented in patients with Sotos syndrome and/or
NSD1 aberrations, especially endocrine and paracrine sys-
tems [33,34].
Etiology
Although most cases are sporadic, autosomal dominant
inheritance has been reported in several cases [35,36].
The report of a child with Sotos syndrome and a
t(5;8)(q35;q24.1) translocation [37], has led to identifica-
tion of the NSD1 gene, which was disrupted by the 5q35
breakpoint (Nuclear receptor SET domain containing pro-
tein) [4]. NSD1 intragenic mutations cause 60% to 80%
of Sotos syndromes cases in Europe and USA, whereas
5q35 microdeletions encompassing NSD1 cause ~ 10% of
cases [5-9,38]. In contrast, NSD1 microdeletions are the
primary cause of Sotos syndrome in Japan, accounting for
over 50% of cases [39-41]. Recently, partial NSD1 dele-
tions were detected in Sotos cases without NSD1 muta-
tion or 5q35 microdeletion [42]. The systematic NSD1
gene screening in a large series of provisional diagnosis of
Sotos and "Sotos-like" syndrome allows to indicate that
NSD1 is mostly found in Sotos patients. NSD1 abnormal-
ities rarely occur in other childhood overgrowth pheno-
types [5-7,43,44]. It is so far unknown whether NSD1
anomalies are involved in other entities. Current studies
are focused on the identification of hotspots for NSD1
mutations or micro deletions and to establish a genotype-
phenotype correlation. Truncating NSD1 mutations
occured throughout the gene, but pathogenic missense
mutations occurred only in functional domains [10,45].
To date, no hypermethylation or sequence abnormalities
in the promotor region have been detected in Sotos
patients [46].
The functions of the NSD1 gene have not been fully estab-
lished. The gene contains 23 exons and encodes a protein
of 2696 amino acids. The protein is a transcriptional inter-
mediary factor and may act as either a nuclear receptor co-
repressor or co-activator by interacting with the holo- or
apoforms respectively, of the ligand binding domain of
different subsets of nuclear hormone receptors. NSD1
expression in human tissue has been detected in fetal/
adult brain, kidney, skeletal, muscle, spleen, lung and thy-
mus [3]. The protein contains multiples functional
domains, including the SET (Su [VAR]3–9, E [Z], tritho-
rax) domain (initially identified in Drosophila genes as
involved in chromatine-mediated regulation during
development) and a SET associated Cys-rich (SAC)
domain adjacent to the SET domain [47]. The combina-
tion of SAC and SET domains is present in proteins that
function as histone-methyltransferase suggesting that
NSD1 may be involved in histone modification and thePage 3 of 6
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NSD1 contains also five plant homeodomains (PHD).
The PHD domain is a zinc finger-like motif that occurs
predominantly in proteins that functions at the chroma-
tin level. NSD1 contains two PWWP (Proline-tryp-
tophane- tryptophane-proline) domains. Their role has
not been established but they are presumably involved in
protein-protein interactions. Finally, NSD1 contains two
distinct nuclear receptor interaction domains [4].
Rare cases of Sotos syndrome have been reported in asso-
ciation with other chromosomal abnormalities: appar-
ently balanced t(3;6) (p21;p21), deletion 15q12, 45, XY,
t(15q;15q) robertsonien translocation [48,49].
Seven to 35% of Sotos patients of the reported series do
not have any NSD1 anomalies. In these patients, the
involvement of the NSD2 and NSD3 genes has been
already excluded by sequencing [50].
Diagnosis methods
Diagnosis is based on clinical exam and radiographic
bone age (cf. clinical description). The clinical diagnosis
can be confirmed by FISH analysis or, if available, by
MLPA (Multiplex Ligation Dependent Probe Amplifica-
tion), a simple and reliable technique to detect 5q35
microdeletion and partial NSD1 deletions (both account
for approximately 15% of the Sotos cases in West Europe
[51]); DNA analysis by sequencing will let to look for
NSD1 mutations.
In patients without NSD1 anomalies, cytogenetic studies
as high resolution karyotyping and comparative genomic
hybridization on microarray techniques may be useful.
Differential diagnosis
Sotos syndrome belongs to a group of overgrowth syn-
dromes that have some clinical features in common such
as pre- and/or postnatal overgrowth and/or advanced
bone age. Many of these syndromes, however, can be eas-
ily excluded on the bases of other major clinical features.
The entities that should be considered in the general dif-
ferential diagnosis of Sotos syndrome are: Weaver syn-
drome; Beckwith-Wiedemann syndrome; Perlman
syndrome; Simpson-Golabi-Behmel syndrome; Fragile X
syndrome; Bannayan-Zonana syndrome; PTEN muta-
tions; Trisomy 15q26-qter; Nevo syndrome; Neurofi-
bromatosis I; Marshall syndrome; Marfan syndrome;
Homocystinuria; Acromegaly.
Genetic counseling
Sotos syndrome is caused by hemizygous mutations in an
autosomal non-imprinted gene. The mental difficulties in
Sotos syndrome are usually in the mild-to-moderate
range, and are not sufficient to account for the extreme
paucity of familial Sotos cases. Fifteen familial cases of
Sotos syndrome have been reported with NSD1 muta-
tions [10,52,53]. It has been suggested that this lack of
family cases is associated with an underlying defect in fer-
tility associated with NSD1 mutations. A three generation
family with NSD1 mutation has been reported [16].
Chromosome analysis of both parent needs to be per-
formed when a deletion of NSD1 is detected in the
affected child. The recurrence risk for a family with an
affected child is very low (<1%). Germline mosaicism has
never been reported.
The identification of NSD1 has been a major step in the
history of Sotos syndrome and has opened a new area in
the elucidation of this condition. The evaluation of the
tumor frequency in patients with NSD1 anomalies will be
important to further define the tumor risk in patients with
Sotos syndrome.
Management and outcome
In the neonatal period, phototherapy is often required
because of jaundice. Sucking and swallowing difficulties
need adjustments of baby food. Alternate methods of
feeding may need to be considered such as the use of a
nasogastric tube. Another common problem is gastro-
esophageal reflux which causes heartburn, vomiting,
esophageal irritation and respiratory problems. Treat-
ments may include adaptations such as eating upright and
elevating the head of the bed, medications and, in rare
cases, surgery. Oral-motor treatment plan may be a part of
the child's therapy program.
Initial systematic screening include renal, cardiac and
orthopedic clinical examination and investigations. Scol-
iosis and vesico-ureteral reflux have to be detected early.
In infancy and the early years, general and specialized
pediatrics follow-up, every one or two year, is still impor-
tant because of the possible clinical events, including con-
stipation, respiratory infections, seizures and because of
the possible increased risk of tumors. Anesthesia may
require special precautions [54].
Early in the childhood, programs including infant stimu-
lation, occupational therapy, speech therapy, and adap-
tive physical education play a significant role in the
nurturing of a child with Sotos syndrome. Later, some
children participate in regular classrooms with support
and some others are enrolled in classes for appropriate
education.
As mentioned previously, some Sotos patients develop
behavior problems during the school age years. As a
result, parents and school staff may have to spend signifi-Page 4 of 6
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problems because they can interfere with learning, social
interaction and family functioning. A psychologist may
work with parents and teachers to develop appropriate
and effective methods.
Final body height is difficult to predict but growth in
height tends to normalize after puberty.
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